Content Conference Coverage Conferences EACS 2015
Coverage of the 15th European AIDS Conference
- Details
- Category: HIV Treatment
- Created on Wednesday, 28 October 2015 00:00
HIVandHepatitis.com coverage of the 15th European AIDS Conference, sponsored by the European AIDS Clinical Society (EACS), October 21-14, 2015, in Barcelona.
Conference highlights include antiretroviral therapy and treatment strategies, new European HIV treatment guidelines, HIV pre-exposure prophylaxis (PrEP), and treatment for hepatitis C.
15th European AIDS Conference website
10/28/15
EACS 2015: Dual Therapy with Protease Inhibitors and Lamivudine Suppresses HIV
- Details
- Category: Approved HIV Drugs
- Created on Monday, 23 November 2015 00:00
Dual antiretroviral regimens consisting of only a boosted HIV protease inhibitor (lopinavir/ritonavir or atazanavir) and a single inexpensive and well-tolerated NRTI may be enough to achieve and maintain HIV suppression in a most patients starting antiretroviral therapy (ART) for the first time or switching from a standard triple regimen, according to a pair of studies presented at the EACS 15th European AIDS Conference last month in Barcelona.
EACS 2015: HIV Maturation Inhibitor BMS-955176 Shows Good Safety and Efficacy in Phase 2a Trial
- Details
- Category: Experimental HIV Drugs
- Created on Tuesday, 27 October 2015 00:00
Bristol-Myers Squibb's next-generation maturation inhibitor BMS-955176 demonstrated good antiviral activity against HIV subtypes B and C in a short proof-of-concept study, and appeared to be safe and well-tolerated, according to findings presented last week at the 15th European AIDS Conference in Barcelona.
EACS 2015: Can Dolutegravir Dual Therapy or Monotherapy Keep HIV Suppressed?
- Details
- Category: Approved HIV Drugs
- Created on Thursday, 22 October 2015 00:00
The potent integrase inhibitor dolutegravir taken with a single well-tolerated NRTI was able to fully suppress viral load in people initiating antiretroviral treatment for the first time, while dolutegravir alone was able to keep HIV suppressed in most treatment-experienced people who started with undetectable viral load, according to a set of studies presented at the 15th European AIDS Conference this week in Barcelona. After these presentations experts offered evidence in favor of and opposed to simplifying treatment by reducing drug burden, disagreeing about whether this strategy is beneficial or too risky.
EACS 2015: TAF Single-Tablet Regimen Shows Good Efficacy, Improved Kidney and Bone Safety
- Details
- Category: Experimental HIV Drugs
- Created on Friday, 23 October 2015 00:00
A single-tablet regimen containing the new tenofovir alafenamide (TAF) -- to be marketed as Genvoya -- suppressed HIV as well as a coformulation containing the older tenofovir disoproxil fumarate (TDF), according to a poster presented this week at the 15th European AIDS Conference in Barcelona. A related studyfound that people who switched from an atazanavir (Reyataz)-based regimen to the new combo had superior virological outcomes, and in both clinical trialsparticipants saw improvements in kidney and bone biomarkers.
More Articles...
- EACS 2015: With EACS Release, All International HIV Treatment Guidelines Agree on When to Start
- EACS 2015: START Substudies Show More Bone Loss with Early ART, But No Differences in Lung or Neurocognitive Function
- EACS 2015: Benefits of Early HIV Treatment Are Clear, But Issues Raised by START and D:A:D Still Unresolved
- EACS 2015: London Clinic Survey Shows Impact of Chemsex on Condom and PEP Use
- EACS 2015: When Will Europe Get PrEP?
- EACS 2015: Modest Bone Loss Seen in Young Men Taking Truvada for Pre-Exposure Prophylaxis
- EACS 2015: Does Low-level HIV Viral Load Raise the Risk of Disease Progression and Comorbidities?
- EACS 2015: Risk of Heart Attack Rises with Length of HIV Infection, Regardless of Age
- EACS 2015: Majority of Migrants with HIV in Europe May Have Acquired Virus in New Country
- EACS 2015: Can Europe Reach the 90-90-90 Target for HIV Treatment by 2020?
- EACS 2015: Sofosbuvir/ Ledipasvir for 8 Weeks Cures Most Hard-to-Treat Hepatitis C in Real Life
- EACS 2015: Hepatitis C Incidence Remains Stable Among HIV-Positive Gay Men in Europe
- EACS 2015: Successful Hepatitis C Treatment Lowers Risk of Death for HIV/HCV Coinfected People
- EACS 2015: Newest MDR-TB Drug Prices Could Fall by Up to 95% Through Generic Production
- EACS 2015: TB Death Rate 4-Fold Higher in Eastern Europe Due to Lack of Treatment after Diagnosis
- EACS 2015: 3-Month Isoniazid/Pyrazinamide Regimen Prevents TB in People with HIV
Web Design and Development by